A detection kit for predicting that efficacy and toxic and side effects of methotrexate in treatment of psoriasis

A detection kit, methotrexate technology, applied in the direction of microbial measurement/testing, biochemical equipment and methods, to achieve the effects of predicting clinical efficacy and side effects, improving clinical efficacy, predicting clinical efficacy and side effects

Active Publication Date: 2019-01-15
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Few studies have focused on the relationship between disease s...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A detection kit for predicting that efficacy and toxic and side effects of methotrexate in treatment of psoriasis
  • A detection kit for predicting that efficacy and toxic and side effects of methotrexate in treatment of psoriasis
  • A detection kit for predicting that efficacy and toxic and side effects of methotrexate in treatment of psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Embodiment 1: Observation of clinical efficacy and side effects of MTX in the treatment of psoriasis

[0012] Materials and Methods

[0013] 1) Psoriasis patients: From January 2015 to June 2017, patients with psoriasis visited the Psoriasis Specialized Clinic of the Department of Dermatology of Huashan Hospital.

[0014] 2) Medication intervention methods:

[0015] During the first and second weeks of treatment, 7.5 mg of MTX was taken orally once a week, 10 mg was taken orally once a week from the third week to the fourth week, and 12.5 mg was taken orally once a week from the fifth week to the 12th week.

[0016] 3) Inclusion criteria

[0017] (1) Age 18-60;

[0018] (2) Patients diagnosed with vulgaris, arthropathic, erythrodermic and pustular psoriasis, body surface area involved (BSA)>10% or psoriasis area and severity index (PASI)> 10;

[0019] (3) Fill out the complete epidemiological survey form and sign the informed consent form.

[0020] 4) Exclusion cr...

Embodiment 2

[0034] Example 2: Correlation between psoriasis susceptibility genes and MTX clinical efficacy

[0035] Materials and Methods

[0036] 1) Extract the DNA of the patients, use the sequenom platform to genotype 18 non-HLA loci in 90 patients, and define the effective group and the ineffective group according to whether they reached PASI75 at 12 weeks. After bioinformatics analysis, it was found that the TNIP1 SNP site rs10036748 Genotypes were statistically significant between the effective group and the ineffective group.

[0037] The results show:

[0038] 2) Comparison of patient information between the effective group and the ineffective group of MTX treatment

[0039]After 12 weeks of MTX treatment, the improvement of PASI75 was regarded as the effective group, and the rest were regarded as the ineffective group. The disease duration of the effective group (19±12) was significantly longer than that of the ineffective group (14±11), and the difference was statistically sig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of biotechnology, relates to a novel genetic marker that predicts clinical efficacy and side effects of MTX. Through studying the relationship between TNIP1 SNP siters10036748 genotype and MTX treatment psoriasis clinical curative effect and liver function damage/liver fibrosis index abnormality, the rs10036748 TT genotype of TNIP1 SNP locus is proposed as a genetic marker to predict the clinical efficacy of MTX in the treatment of psoriasis and liver damage. A detection kit for predicting that clinical efficacy and side effect of methotrexate in the treatment of psoriasis is further provided. The marker and the kit can be used for predicting the clinical curative effect and side effect evaluation of MTX in treating psoriasis, are helpful for guiding clinicians to formulate a suitable MTX treatment intervention scheme, and provide a basis for improving the clinical efficacy of methotrexate and reducing toxicity and side effects.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a detection kit for predicting the curative effect and side effects of methotrexate (MTX), in particular to a novel detection reagent that can be used to predict the clinical curative effect and toxic and side effects of methotrexate in the intervention treatment of psoriasis Kit, the kit predicts the clinical intervention efficacy and side effects of MTX by detecting the SNP site of the susceptibility gene TNIP1 in psoriasis patients. Background technique [0002] The prior art discloses that psoriasis is a common chronic inflammatory disease that can affect multiple organs such as skin, nails, joints, kidneys, and cardiovascular. Due to the high incidence of the disease, long course of disease, easy recurrence, and difficult to cure, it brings serious physical and mental damage and economic burden to patients. Among the drug interventions commonly used in clinical practice, the effe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/106C12Q2600/172C12Q2600/156
Inventor 徐金华颜克香张学军
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap